Effects of statins on the liver: Clinical analysis of patients with ischemic stroke

Chinese Medical Journal

Volumn 124, Issue 6, 2011, Pages 897-900

  Zhang, Li San ^a   Liu, Zheng Xia ^a   Lü, Wen ^a   Hu, Xing Yue ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Alanine aminotransferase; Aspartate aminotransferase; Ischemic stroke; Liver function; Statins

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; ESSENTIALE; FLUINDOSTATIN; GLUTATHIONE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN ISCHEMIA; CHRONIC LIVER DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FATTY LIVER; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTRANSAMINASEMIA; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; LIVER; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; TREATMENT RESPONSE;

AGE DISTRIBUTION; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STROKE;

EID: 79952820573     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.06.017     Document Type: Article

References (21)

1. Grigore L, Norata GD, Catapano AL. Combination therapy in cholesterol reduction: focus on ezetimibe and statins. Vasc Health Risk Manag 2008; 4: 267-278
2. Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative Group. Effects of cholesterollowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363: 757-767
3. Nassief A, Marsh JD. Statin therapy for stroke prevention. Stroke 2008; 39: 1042-1048
4. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-559
5. Cimino M, Gelosa P, Gianella A, Nobili E, Tremoli E, Sironi L. Statins: multiple mechanisms of action in the ischemic brain. Neuroscientist 2007; 13: 208-213
6. Stepień K, Tomaszewski M, Czuczwar SJ. Neuroprotective properties of statins. Pharmacol Rep 2005; 57: 561-569
7. Athyros VG, Kakafika AI, Tziomalos K, Papageorgiou AA, Karagiannis A. Statins for the prevention of first or recurrent stroke. Curr Vasc Pharmacol 2008; 6: 124-133
8. Vasudevan AR, Hamirani YS, Jones PH. Safety of statins: effects on muscle and the liver. Cleve Clin J Med 2005; 72: 990-993, 996-1001
9. Koren MJ, Feldman T, Mendes RA. Impact of high-dose atorvastatin in coronary heart disease patients age 65 to 78 years. Clin Cardiol 2009; 32: 256-263
10. McKenney JM. An assessment of statin safety. Am J Manag Care 2006; 12: S310-S317.
11. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119: e21-e181.
12. Reeves MJ, Gargano JW, Luo Z, Mullard AJ, Jacobs BS, Majid A, et al. Effect of pretreatment with statins on ischemic stroke outcomes. Stroke 2008; 39: 1779-1785
13. Shen CX, Chen HZ, Ge JB. The role of inflammatory stress in acute coronary syndrome. Chin Med J 2004; 117:133-139
14. de Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004; 24: 584-591
15. Alsheikh-Ali AA, Karas RH. The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: evidence from clinical trials. Curr Atheroscler Rep 2009; 11: 100-104
16. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998; 19: 26-37
17. Cohen DE, Anania FA, Chalasani N, National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol 2006; 97: 77C-81C.
18. Pfeffer MA, Keech A, Sacks FM, Cobbe SM, Tonkin A, Byington RP, et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 2002; 105: 2341-2346
19. Willrich MA, Hirata MH, Hirata RD. Statin regulation of CYP3A4 and CYP3A5 expression. Pharmacogenomics 2009; 10: 1017-1024
20. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005; 41: 690-695
21. Vuppalanchi R, Chalasani N. Statins for hyperlipidemia in patients with chronic liver disease: are they safe? Clin Gastroenterol Hepatol 2006; 4: 838-839